FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

Updated on: March 30,2024

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

Updated on:March 30,2024

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial

by University of ExeterA large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in pe

Updated on: March 07,2024

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial

by University of ExeterA large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in pe

Updated on:March 07,2024

How Alzheimer's disease spreads throughout the brain – new study

by Thomas E Cope,The ConversationHarmful tau protein spreads through networks.Alzheimer's disease is a devastating brain illness that affects anestimated 47m peopleworldwide. It

Updated on: April 10,2024

How Alzheimer's disease spreads throughout the brain – new study

by Thomas E Cope,The ConversationHarmful tau protein spreads through networks.Alzheimer's disease is a devastating brain illness that affects anestimated 47m peopleworldwide. It

Updated on:April 10,2024

Brain exercise and training program to improve mind and body wellness in individuals with mild cognitive impairment

by Courtney Caprara,University of PittsburghIndividuals with mild cognitive impairment have a new resource in Pittsburgh with the recently establishedBrain Training and Exercise(BRiT

Updated on: March 07,2024

Brain exercise and training program to improve mind and body wellness in individuals with mild cognitive impairment

by Courtney Caprara,University of PittsburghIndividuals with mild cognitive impairment have a new resource in Pittsburgh with the recently establishedBrain Training and Exercise(BRiT

Updated on:March 07,2024

Increased chances for early detection of Alzheimer's disease

by Lund UniversityA method for detecting early signs of Alzheimer's disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the concl

Updated on: February 26,2024

Increased chances for early detection of Alzheimer's disease

by Lund UniversityA method for detecting early signs of Alzheimer's disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the concl

Updated on:February 26,2024

Research holds promise for Alzheimer's diagnostic blood test

by University of OtagoUniversity of Otago researchers have discovered a promising new marker that could help diagnose Alzheimer's disease—and all that might be required is a simple blood test

Updated on: February 28,2024

Research holds promise for Alzheimer's diagnostic blood test

by University of OtagoUniversity of Otago researchers have discovered a promising new marker that could help diagnose Alzheimer's disease—and all that might be required is a simple blood test

Updated on:February 28,2024

FDA approves much-debated Alzheimer's drug panned by experts

by Matthew PerroneIn this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administratio

Updated on: March 30,2024

FDA approves much-debated Alzheimer's drug panned by experts

by Matthew PerroneIn this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administratio

Updated on:March 30,2024

New figures show dementia is leading cause of death in England and Wales

by Alzheimer's Research UKNew figures released by the Office of National Statistics show that for the first time, Alzheimer's disease and other dementias are the leading cause of death fo

Updated on: March 07,2024

New figures show dementia is leading cause of death in England and Wales

by Alzheimer's Research UKNew figures released by the Office of National Statistics show that for the first time, Alzheimer's disease and other dementias are the leading cause of death fo

Updated on:March 07,2024

Early abnormalities of Alzheimer's disease: It takes two (proteins) to tango

by McGill UniversityCredit: McGill UniversityFor years, neuroscientists have puzzled over how two abnormal proteins, called amyloid and tau, accumulate in the brain and damage it to cause Alzheim

Updated on: February 28,2024

Early abnormalities of Alzheimer's disease: It takes two (proteins) to tango

by McGill UniversityCredit: McGill UniversityFor years, neuroscientists have puzzled over how two abnormal proteins, called amyloid and tau, accumulate in the brain and damage it to cause Alzheim

Updated on:February 28,2024

New indication of a link between Alzheimer's and diabetes

by Forschungszentrum JuelichIllustration of IAPP fibrils. Credit: Forschungszentrum Jülich/HHU Düsseldorf/Gunnar SchröderPathological protein clumps are characteristic of a series of diseases, su

Updated on: April 10,2024

New indication of a link between Alzheimer's and diabetes

by Forschungszentrum JuelichIllustration of IAPP fibrils. Credit: Forschungszentrum Jülich/HHU Düsseldorf/Gunnar SchröderPathological protein clumps are characteristic of a series of diseases, su

Updated on:April 10,2024

Alzheimer's drug gantenerumab fails to slow decline in phase III clinical trial

by Alzheimer's Research UKCredit: Pixabay/CC0 Public DomainThe pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer's drug gantenerumab did not

Updated on: April 16,2024

Alzheimer's drug gantenerumab fails to slow decline in phase III clinical trial

by Alzheimer's Research UKCredit: Pixabay/CC0 Public DomainThe pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer's drug gantenerumab did not

Updated on:April 16,2024

How inflammation alters nerve cell responses to make touch painful

Updated on: May 15,2025

How inflammation alters nerve cell responses to make touch painful

Updated on:May 15,2025